Sorry, you need to enable JavaScript to visit this website.
Skip to main content

First Human Clinical Trial Results on the Anti-Aging Compound, Urolithin A, Published by Amazentis and Researchers from the EPFL and SIB

First Human Clinical Trial Results on the Anti-Aging Compound, Urolithin A, Published by Amazentis and Researchers from the EPFL and SIB

Breakthrough translational science of dietary supplementation with Urolithin A, a pomegranate metabolite, on mitochondrial and cellular health in humans published in the journal Nature Metabolism

Lausanne, Switzerland, June 14, 2019 -- Amazentis, an innovative life sciences company pioneering scientific breakthroughs in nutrition to manage health conditions linked to aging, announced today a collaborative publication in Nature Metabolism with scientists at the École Polytechnique Fédérale de Lausanne (EPFL) and the Swiss Institute of Bioinformatics (SIB) demonstrating the Company’s lead product, Urolithin A (UA), is safe, bioavailable and improves mitochondrial and cellular health in humans.

UA was orally administered in both single and multiple (4 weeks) daily dosing to 60 healthy elderly subjects in a double-blind, randomized, placebo-controlled study. The trial showed that regular UA dosing during 4 weeks is safe, bioavailable and effective in improving mitochondrial health through upregulation of mitochondrial gene expression localized to the skeletal muscle and by improving systemic plasma acylcarnitines associated with cellular and mitochondrial function.

Roger Fielding, PhD, Professor of Nutrition and Medicine at Tufts University, commented, “Other than exercise, there are currently no effective solutions to treat age-related decline in muscle function. This is an important study that shows that the metabolite of ellagitannins, Urolithin A, upregulates specific genes involved in mitochondrial protein synthesis and may be a possible avenue for improving muscle health in older adults.”

“Mitochondrial and cellular health declines with age, making these results a pivotal milestone as we explore the full breadth of benefits Urolithin A offers for managing human health throughout the aging process,” stated Patrick Aebischer, MD, co-author on the article, EPFL President Emeritus, and Chairman and Co-founder of Amazentis.
“These latest findings, which build on previous preclinical trials, really crystallize how UA could be a game-changer for human health,” added Johan Auwerx, MD, PhD, co-author and Professor at the EPFL.

Nestlé Health Science recently announced a global partnership with Amazentis to develop products containing UA to pursue opportunities in consumer healthcare and medical nutrition.
Chris Rinsch, PhD, lead author, Co-founder and CEO of Amazentis, said, “The rigorous clinical science being published in Nature Metabolism is a critical step towards translating our breakthrough scientific discoveries in nutrition into clinically validated consumer health products that address today’s unmet needs for healthy aging.”

The results are being reported in the current issue of Nature Metabolism in an article titled, “The mitophagy activator Urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans” (doi: 10.1038/s42255-019-0073-4).

Amazentis Nature Metabolism Press Release